Minerva Neurosciences Reports Topline Results From Phase 2b Trial of MIN-117 in Major Depressive Disorder
18 déc. 2019 16h05 HE
|
Minerva Neurosciences, Inc
MIN-117 study did not meet its primary (MADRS) and key secondary (HAM-A) endpointsMIN-117 was generally well-tolerated with a safety profile comparable to placeboCompany to host conference call at...
Minerva Neurosciences to Present at Jefferies London Healthcare Conference on November 21, 2019
14 nov. 2019 08h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
Minerva Neurosciences Reports Third Quarter 2019 Financial Results and Business Updates
04 nov. 2019 07h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences to Report Third Quarter 2019 Financial Results and Business Updates on November 4, 2019
28 oct. 2019 08h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Announces Update for Three Clinical Trials
01 oct. 2019 07h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences to Host Conference Call and Live Webcast on Tuesday, October 1 at 8:30 AM ET
26 sept. 2019 16h10 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Catalent and Minerva Neurosciences Enter Commercial Supply Agreement for Schizophrenia Drug Roluperidone
24 sept. 2019 09h00 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass. and SOMERSET, N.Y., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative...
Minerva Neurosciences Reports Second Quarter 2019 Financial Results and Business Updates
05 août 2019 07h30 HE
|
Minerva Neurosciences, Inc
During the Second Quarter, Minerva announced several important clinical advancements, including positive top line results from two Phase 2b studies of seltorexant (MIN-202) in major depressive...
Minerva Neurosciences to Report Second Quarter 2019 Financial Results and Business Updates on August 5, 2019
29 juil. 2019 08h00 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., July 29, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Announces Achievement of Primary and Key Secondary Objectives in Phase 2b Clinical Trial of Seltorexant (MIN-202) in Insomnia
24 juin 2019 07h30 HE
|
Minerva Neurosciences, Inc
Primary endpoint, defined as Latency to Persistent Sleep (LPS) at Night 1, showed improvement with a p-value ≤0.001 after treatment with 10 and 20 mg doses of seltorexantKey secondary endpoint,...